Roivant, Organon
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...
Top of the morning to you and a fine one it is. Blue skies, cool breezes and plenty of chirping birds are enveloping the ...
Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate ...
Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...
Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed ...
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback